1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,300 | 22,500 | 19.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.09. | BASTIDE: Revenue for 2025-2026, excluding the impact of the sale of EXPERF: EUR 526 million, exceeding the target 2025-2026 revenue as reported: EUR 483 million, up 7.6% Recurring operating margin target of around 9% confirmed | 441 | Actusnews Wire | Caissargues, September 3, 2026
Groupe Bastide, a leading European provider of home healthcare services, has published its annual revenue for 2025-2026. In accordance with IFRS 5, reported revenue... ► Artikel lesen | |
| 01.06. | BASTIDE: Completion of the disposal of New Medical Concept, the holding company of EXPERF Group, to Sapio Group | 548 | Actusnews Wire | Caissargues, 1st June 2026 - Bastide Group announces the completion of the acquisition by Sapio Group of its subsidiary New Medical Concept, the holding company of the French EXPERF Group, a specialist... ► Artikel lesen | |
| 21.05. | BASTIDE: Groupe Bastide sells New Medical Concept, the holding company of EXPERF group - Erratum | 596 | Actusnews Wire | Caissargues, 21 May 2026 -Groupe Bastide today announced the signing of an agreement for the disposal of its subsidiary New Medical Concept, the holding company of the French group EXPERF, specialized... ► Artikel lesen | |
| 21.05. | BASTIDE: Groupe Bastide sells New Medical Concept, the holding company of EXPERF group | 554 | Actusnews Wire | Caissargues, 21 May 2026 -Groupe Bastide today announced the signing of an agreement for the disposal of its subsidiary New Medical Concept, the holding company of the French group EXPERF, specialized... ► Artikel lesen | |
| 13.05. | BASTIDE: Strong momentum for the first nine months of the financial year: up 7.2% on an organic basis | 820 | Actusnews Wire | Sustained growth in home healthcare services: up 8.5%
Solid growth of 5.2% in Homecare, including the one-off impact of the VPH* reform in the third quarter
2025-2026 targets confirmed
Caissargues... ► Artikel lesen | |
| 18.03. | BASTIDE: 2025-2026 half-year results | 1.100 | Actusnews Wire | Recurring operating margin: 9.0%, in line with the annual target
Operating profit up 12.5%
Operating free cash flow: €24.3 million, a threefold increase in one year
Significant improvement... ► Artikel lesen | |
| 12.02. | BASTIDE: Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed | 529 | Actusnews Wire | Caissargues, February 12, 2026 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-half 2025-2026, ending December 31, 2025.
In... ► Artikel lesen | |
| 13.11.25 | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 573 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 28.10.25 | BASTIDE: 2025-2026 financial calendar | 1.121 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| 22.10.25 | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 1.050 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| 24.09.25 | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 894 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BILLIONTOONE | 105,92 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| FRESENIUS | 45,920 | -0,42 % | Vonovia sackt ab, Fresenius zieht an: DAX-Ausblick | Der DAX hat sich der abgelaufenen Woche weiter von seinem Rekordhoch entfernt. Unter dem Strich büßte das größte deutsche Börsenbarometer fast 500 Punkte ein und schloss -1,87% tiefer mit 25.559 Punkten.... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,770 | -1,69 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,690 | -0,79 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| PROGYNY | 27,130 | 0,00 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| MIMEDX | 4,770 | 0,00 % | Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8 | ||
| BRIGHTSPRING HEALTH SERVICES | 56,76 | 0,00 % | Here's Why You Should Add BrightSpring Stock to Your Portfolio Now | ||
| BETA BIONICS | 21,890 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its... ► Artikel lesen | |
| HEARTFLOW | 50,65 | -0,20 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,335 | -0,18 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| ANTERIS TECHNOLOGIES GLOBAL | 8,160 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Compensatory Arrangements of Certain Officers | ||
| LIFESTANCE HEALTH GROUP | 12,575 | +0,04 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| AVEANNA HEALTHCARE | 13,655 | -0,11 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| CARL ZEISS MEDITEC | 29,460 | +1,52 % | SFC Energy, Dürr, Carl Zeiss Meditec, SFC Energy schauen nach Dehli zum BRIC's Gipfel - und Trump golft | Zeitenwende. Die Musik spielt in Dehli. Carl Zeiss MediTec, SFC Energy, Dürr, Wacker Chemie - you name it. Deutsche Small- und MidCaps müssen die Chance der Veränderung nutzen. Vielelicht noch mehr... ► Artikel lesen | |
| GENEDX | 101,09 | -0,01 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug |
Das Unternehmen BASTIDE LE CONFORT MEDICAL SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 21,250 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BASTIDE LE CONFORT MEDICAL SA finden Sie auf Wallstreet Online.